[Long term therapy of XXXX with 120 mg slow release @entity3763 once a day. Study of duration of action and development of tolerance].

@entity1 @entity308 @entity3763 @entity301
Twenty-one @entity1 (3 @entity1 , 18 males, mean age 55.7 +/- 6 years) with @entity301 proven by coronary angiography entered a double blind randomised study with @entity3763 slow release 120 mg once a day. 2, 12 and 24 hours after acute medication @entity1 underwent a symptom-limited exercise-ECG. The following parameters were measured: @entity308 , blood pressure, heart rate and working capacity. After one week of therapy the same parameters were measured to look for the development of tolerance. Two and twelve hours after acute medication working capacity increased to 220% and 139% respectively. After 24 hours there was no statistically significant effect. The sum of @entity308 in three leads decreased from 4.85 +/- 3.02 mV to 1.87 +/- 0.96 mV (38.5%; p less than 0.05) 2 hours after medication, and to 2.10 +/- 1.73 mV 12 hours after medication. 24 hours after medication there was still a slight but not significant @entity308 . There was no statistically significant effect in the placebo group. After one week of therapy there was a slight reduction of action, but no development of tolerance.
